Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.
A link to the prescribing information can be found in the header.

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated in adults for symptomatic treatment of spasmodic torticollis

Please click here to see the full therapeutic indications.

CLIMB Online
Cervical Dystonia

Making sense of the changing NHS and funding flows

12 minutes

Dr Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.

DYS-UK-007356

Navigating the Switch between BoNT-As: The North Staffordshire Rehabilitation Centre Experience

10 minutes

Dr Clive Bezzina shares his personal experience switching between BoNT-As within his spasticity service, and the outcomes seen for both the patients and the service.

DYS-UK-007573

Dysport® Dilution Guide

2 pages

A downloadable reference guide to reconstituting and diluting Dysport®

DYS-UK-007576

BoNT Immunogenicity: The difference between neutralising and non-neutralising antibodies

3 minutes

Understand the difference between neutralising and non-neutralising antibodies and how this difference should be considered during clinical decision-making.

DYS-UK-007538

Flexibility with Dysport in Clinical Practice: A case study (36F with CD)

5 minutes

Presented by: Dr Tim Harrower

DYS-UK-007571

Demystifying the Clinical Relevance of BoNT Immunogenicity

5 minutes

Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment

Presented by: Dr Tim Harrower

DYS-UK-007574

Dysport® Mechanism of Action

3 minutes

DYS-UK-007580